Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapiesReuters • 10/03/23
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket PharmaceuticalsThe Motley Fool • 09/23/23
Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could DoubleThe Motley Fool • 09/10/23
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks AgainThe Motley Fool • 08/30/23
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy TrialGlobeNewsWire • 08/30/23
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/03/23
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 08/03/23
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company UpdatesGlobeNewsWire • 07/27/23
Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?The Motley Fool • 06/23/23
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?The Motley Fool • 06/21/23